Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity

Blood

Volumn 94, Issue 12, 1999, Pages 4263-4273

  Dunussi Joannopoulos, Kyriaki ^a   Runyon, Kathlene ^b   Erickson, Jamie ^b   Schaub, Robert G ^b   Hawley, Robert G ^b   Leonard, John P ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 0032779055     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.12.4263     Document Type: Article

References (66)

1. Pardoll DM: Cancer vaccines. Nat Med 4:525, 1998
2. Hodi FS, Dranoff G: Genetically modified tumor cell vaccines. Cancer Gene Ther 7:471, 1998
3. Simons JW, Mikhak B: Ex-vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology. Semin Oncol 25:661, 1998
4. Nanda NK, Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 82:13, 1995
5. Sotomayor EM, Borrello I, Levitsky HI: Tolerance and cancer: A critical issue in tumor immunology. Crit Rev Oncog 7:433, 1996
6. Schwartz RH: Costimulation of T lymphocytes: The Role of CD28, CTLA-4, and B7//BB1 in interleukin-2 production and immunotherapy. Cell 71:1065, 1992
7. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 15:321, 1994
8. Palm N, Germann T, Goedert S, Hoehn P, Koelsch S, Rude E, Schmitt E: Co-development of naive CD4+ cells towards T helper type 1 or T helper type 2 cells induced by a combination of IL-12 and IL-4. Immunobiology 196:475, 1996
9. Wenner CA, Guler ML, Macatonia SE, O'Garra A, Murphy KM: Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 156:1442, 1996
10. Bradley LM, Dalton DK, Croft M: A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol 157:1350, 1996
11. Chen L, Linsley PS, Hellström KE: Costimulation of T cells for tumor immunity. Immunol Today 14:483, 1993
12. Dranoff G, Mulligan RC: Gene transfer as cancer therapy. Adv Immunol 58:417, 1995
13. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399, 1995
14. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley P: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093, 1992
15. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368, 1993
16. Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, Blazar BR: The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Blood 89:3477, 1997
17. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan R: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539, 1993
18. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW: Immunization with GM-CSF-transduced, but not B7-1-transduced lymphoma cells primes idiotype-specific T cells and generates potent anti-tumor immunity. J Immunol 156:3858, 1996
19. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, 3rd, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154:6466, 1995
20. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL: Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 7:1995, 1996
21. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT: Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 26:1335, 1996
22. Pizzoferrato E, Chu NR, Hawley TS, Lieu FH, Barber BH, Hawley RG, Watts TH, Berinstein NL: Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12. Hum Gene Ther 8:2217, 1997
23. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827, 1989
24. Brunda MJ: Interleukin-12. J Leukoc Biol 55:280, 1994
25. Trinchieri G: Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv Immunol 70:83, 1998
26. Trinchieri G: Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008, 1994
27. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153:1697, 1994
28. Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T: Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 7:1135, 1995
29. Mu J, Zou JP, Yamamoto N, Tsutsui T, Tai XG, Kobayashi M, Herrmann S, Fujiwara H, Hamaoka T: Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 55:4404, 1995
30. Hunter SE, Waldburger KE, Thibodeaux DK, Schaub RG, Goldman SJ, Leonard JP: Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: Cellular and cytokine-mediated effector mechanisms. Eur J Immunol 27:3438, 1997
31. Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, Woerly G, Huang S, Aguet M, Anderson TD, Ryffel B: Role of interferon-gamma in interleukin 12-induced pathology in mice. Am J Pathol 147:1693, 1995
32. Coughlin CM, Wysocka M, Trinchieri G, Lee WM: The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 57:2460, 1997
33. Chen L, Chen D, Block E, O'Donnell M, Kufe DW, Clinton SK: Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 159:351, 1997
34. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK: Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol 17:71, 1995
35. Houghton AN, Thomson TM, Gross D, Oettgen HF, Old LJ: Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med 160:255, 1984
36. Yu WG, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H, Hamaoka T: IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol 62:450, 1997
37. Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WM: Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J Exp Med 188:1603, 1998
38. Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM, Hamilton TA: Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 156:693, 1996
39. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161:927, 1998
40. Coughlin CM, Salhany KE, Wysocka M, Araga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G, Lee WMF: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101:1441, 1998
41. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WM: Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25, 1998
42. Vitale A, Guarini A, Latagliata R, Cignetti A, Foa R: Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts. Br J Haematol 101:150, 1998
43. Stine KC, Warren BA, Becton DL: Interleukin-12 (IL-12) enhances lysis of non-lymphoid leukemia cell lines in vitro. Leukemia 12:1204, 1998
44. Appelbaum FR, Kopecky KJ: Long-term survival after chemotherapy for acute myeloid leukemia: The experience of the Southwest Oncology Group. Cancer 80:2199, 1997
45. Burnett AK, Eden OB: The treatment of acute leukemia. Lancet 349:270, 1997
46. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, Strom TB, Burakoff SJ, Croop JM, Arceci RJ: Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87:2938, 1996
47. Dunussi-Joannopoulos K, Weinstein HJ, Arceci RJ, Croop JM: Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model. J Pediatr Hematol Oncol 19:536, 1997
48. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD: Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507, 1995
49. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD: B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 156:1126, 1996
50. Lieu FH, Hawley TS, Fong AZ, Hawley RG: Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: Implications for immune gene therapy. Cancer Gene Ther 4:167, 1997
51. Colombo MP, Forni G: Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol Today 15:48, 1994
52. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL, Forni G: Cytokines, tumour-cell death and immunogenicity: A question of choice. Immunol Today 18:32, 1997
53. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM: Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 91:222, 1998
54. Trinchieri G: Immunobiology of interleukin-12. Immunol Res 17:269, 1998
55. Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, Wigginton JM, Wiltrout RH, Hendrzak JA, Palleroni AV: Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 38:516, 1996
56. Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, Biron CA: Mechanism of interleukin 12-mediated toxicities during experimental viral infections: Role of tumor necrosis factor and glucocorticoids. J Exp Med 181:901, 1995
57. Cohen J: IL-12 deaths: Explanation and a puzzle. Science 270:208, 1995
58. Kaminsky SG, Millisauskas V, Chen PB, Nakamura I: Defective differentiation of natural killer cells in SJL mice. Role of the thymus. J Immunol 138:1020, 1987
59. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541, 1997
60. Hasan M, Najjam S, Gordon MY, Gibbs RV, Rider CC: IL-12 is a heparin-binding cytokine. J Immunol 162:1064, 1999
61. Deeths MJ, Mescher MF: ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1. Eur J Immunol 29:45, 1999
62. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581, 1995
63. Angiolillo AL, Sgadari C, Tosato G: A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 795:158, 1996
64. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353, 1996
65. Folkman J: Addressing tumor blood vessels. Nat Biotechnol 6:510, 1997
66. Beverley PC: Is T-cell memory maintained by crossreactive stimulation? Immunol Today 11:203, 1990